Physician profile
Eric P West
NPI 1003985201
$2,492.33
in general payments reported to CMS, 2019-2025
21 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $112 · 2021: $503 · 2022: $476 · 2023: $320 · 2024: $44.84 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $623.93 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $265.49 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $238.57 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $188.79 | 2023-2025 | Miebo, Infuse, Xiidra |
| Optos, INC. | $173.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Allergan, INC. | $124.74 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $124.12 | 2022 | |
| Glaukos Corporation | $122.28 | 2021 | |
| Dompe US, INC. | $78.00 | 2023 | Oxervate |
| Abbvie INC. | $76.68 | 2022-2023 | Vuity |
| Lkc Technologies, INC. | $71.14 | 2023 | |
| Kala Pharmaceuticals, INC. | $62.91 | 2019 | |
| Apellis Pharmaceuticals, INC. | $57.00 | 2025 | Syfovre |
| Oyster Point Pharma, INC. | $44.80 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $27.69 | 2024 | |
| Sight Sciences, INC. | $20.43 | 2023 | Tearcare System |
| Csl Behring | $19.33 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Harrow Eye, LLC | $16.96 | 2025 | Vevye |
| Lombart Brothers, INC. | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.